P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

被引:26
|
作者
Thuault, S. [1 ,2 ]
Hayashi, S. [3 ]
Lagirand-Cantaloube, J. [1 ,2 ]
Plutoni, C. [1 ,2 ]
Comunale, F. [1 ,2 ]
Delattre, O. [4 ]
Relaix, F. [3 ]
Gauthier-Rouviere, C. [1 ,2 ]
机构
[1] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[2] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[3] INSERM UPMC AIM, UMRS787, Paris, France
[4] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France
关键词
P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch; TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION;
D O I
10.1038/onc.2012.217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 50 条
  • [41] The PAX3-FOXO1 oncogene drives aneuploidy and overrides aneuploidy-associated proliferative defects in alveolar rhabdomyosarcoma
    Hollenbach, Andrew D.
    Loupe, Jacob M.
    Miller, Patrick J.
    Bonner, Benjamin P.
    Maggi, Elaine C.
    Vijayaraghavan, Jyothi
    Zabaleta, Jovanny
    Taylor, Christopher M.
    Miller, Fern
    Crabtree, Judy S.
    CANCER RESEARCH, 2016, 76
  • [42] Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options
    Loupe, J. M.
    Miller, P. J.
    Ruffin, D. R.
    Stark, M. W.
    Hollenbach, A. D.
    ONCOGENESIS, 2015, 4 : e145 - e145
  • [43] PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome
    Ohkawa, Teppei
    Nishimura, Akira
    Kosaki, Kenjiro
    Aoki-Nogami, Yuki
    Tomizawa, Daisuke
    Kashimada, Kenichi
    Morio, Tomohiro
    Kato, Motohiro
    Mizutani, Shuki
    Takagi, Masatoshi
    JOURNAL OF HUMAN GENETICS, 2022, 67 (01) : 51 - 54
  • [44] PAX3-FOXO1: Zooming in on an "undruggable" target
    Wachtel, Marco
    Schafer, Beat W.
    SEMINARS IN CANCER BIOLOGY, 2018, 50 : 115 - 123
  • [45] RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy
    Rengaswamy, Venkatesh
    Zimmer, Doris
    Suess, Regine
    Roessler, Jochen
    JOURNAL OF CONTROLLED RELEASE, 2016, 235 : 319 - 327
  • [46] PLK1 regulates PAX3-FOXO1 stability and its inhibition mediates regression of alveolar rhabdomyosarcoma xenograft tumors
    Thalhammer, Verena
    Herrero-Martin, David
    Hecker, Regina
    Laubscher, Dominik
    Lopez-Garcia, Laura
    Wachtel, Marco
    Bode, Peter
    Schaefer, Beat
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma
    Kephart, Julie J. G.
    Tiller, Rosanne G. J.
    Crose, Lisa E. S.
    Slemmons, Katherine K.
    Chen, Po-Han
    Hinson, Ashley R.
    Bentley, Rex C.
    Chi, Jen-Tsan Ashley
    Linardic, Corinne M.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4868 - 4880
  • [48] Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?
    Guram, Sheena
    Dirks, Julia
    Barot, Shivali
    Griffin, Anthony
    Weinreb, Ilan
    Demicco, Elizabeth
    Shultz, David Benjamin
    Razak, Albiruni Ryan Abdul
    Gladdy, Rebecca Anne
    Gupta, Abha A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] PAX3-FOXO1 is essential for initiation but not for recurrence during rhabdomyosarcoma tumorigenesis
    Pandey, Puspa R.
    Hewitt, Stephen M.
    Miettinen, Markku M.
    Barr, Frederic G.
    CANCER RESEARCH, 2015, 75
  • [50] FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
    David Milewski
    Samriddhi Shukla
    Berkley E. Gryder
    Arun Pradhan
    Johnny Donovan
    Parvathi Sudha
    Sushmitha Vallabh
    Athena Pyros
    Yan Xu
    Artem Barski
    Sara Szabo
    Brian Turpin
    Joseph G. Pressey
    Douglas P. Millay
    Javed Khan
    Vladimir V. Kalinichenko
    Tanya V. Kalin
    Oncogene, 2021, 40 : 2182 - 2199